Maze Therapeutics, Inc.
(MAZE)Financial Statements · SEC EDGAR XBRL
Net Income
-$131.1M
-351.0%
EPS
$-3.05
-344.0%
Op. Income
-$142.9M
-348.1%
FCF
-$112.7M
-250.7%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)